Brazikumab
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease[1].
Product Specifications
CAS Number
[1610353-18-8]
Product Name Alternative
AMG 139; MEDI2070
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/brazikumab.html
Purity
95.00
Solubility
H2O
Smiles
[Brazikumab]
Molecular Weight
(144.82 kDa)
References & Citations
[1]Currò D, et, al. Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Front Pharmacol. 2017 Jun 23;8:400.|[2]Al-Bawardy B, et, al. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021 Apr 14;12:651415.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-23
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1010395-01 0.02 mg (E-Coli)
Recombinant Escherichia coli O45:K1 Divalent-cation tolerance protein CutA (cutA)
Ask
View Details 
MBS1010395-02 0.1 mg (E-Coli)
Recombinant Escherichia coli O45:K1 Divalent-cation tolerance protein CutA (cutA)
Ask
View Details 
MBS1010395-03 0.02 mg (Yeast)
Recombinant Escherichia coli O45:K1 Divalent-cation tolerance protein CutA (cutA)
Ask
View Details MBS1010395-04 0.1 mg (Yeast)
Recombinant Escherichia coli O45:K1 Divalent-cation tolerance protein CutA (cutA)
Ask
View Details MBS1010395-05 0.02 mg (Baculovirus)
Recombinant Escherichia coli O45:K1 Divalent-cation tolerance protein CutA (cutA)
Ask
View Details